Tempus AI Acquires Paige Digital Pathology Firm for $81M

Tempus AI has acquired the digital pathology developer Paige for $81.25 million, primarily through Tempus stock and assuming Paige's remaining Microsoft Azure cloud service commitments. This acquisition significantly expands Tempus's dataset with nearly 7 million digitized pathology slides and clinical data licensed from Memorial Sloan Kettering Cancer Center, as well as enhances its AI capabilities with Paige's foundation AI model trained on over 2.3 million whole-slide images. Tempus aims to accelerate its efforts in building the largest foundation model in oncology, leveraging Paige's expertise in digital pathology and generative AI. The deal also strengthens Tempus's foothold in digital pathology, which supports improved cancer detection and drug development. Following the announcement, Tempus shares experienced a notable rise, reflecting investor optimism about the acquisition's growth potential. Overall, this strategic move bolsters Tempus's position in healthcare technology and precision oncology research.